Hims & Hers Health Surges After RFK Jr. Bypasses FDA to Allow Unapproved Peptide Access

HHS Secretary RFK Jr.'s decision to ease FDA restrictions on unapproved peptides sent Hims stock sharply higher as investors priced in an expanded market.

• Hims stock surged after RFK Jr. circumvented FDA to green-light unapproved peptides
• Move expands addressable market for compounding pharmacies and DTC health platforms
• Regulatory shift signals broader FDA authority reduction under RFK Jr. at HHS

The RFK Jr. peptide decision is a significant regulatory catalyst for the direct-to-consumer health sector. By bypassing standard FDA approval pathways to permit access to unapproved peptides — a category that includes compounds used in weight loss, performance, and longevity applications — HHS has expanded the total addressable market for platforms like Hims & Hers that distribute through licensed compounding pharmacies. Investors immediately priced in the upside, sending HIMS shares sharply higher in Wednesday trading.

The mechanism matters for investors assessing durability. RFK Jr.'s authority to override FDA scheduling without congressional action is legally contested, meaning the regulatory tailwind could face judicial challenge. If courts uphold the decision, Hims gains a sustainable competitive advantage in a category where GLP-1 adjacency has already driven outsized revenue growth. If challenged, the stock may give back gains as the market reprices the probability of sustained access. The legal risk profile is asymmetric and worth monitoring closely.

Competitors in the compounding and DTC health space — Ro, Keeps, Noom, and other subscription wellness platforms — will benefit similarly if the decision holds. But Hims's first-mover brand recognition and existing subscriber base positions it to capture disproportionate share of incremental demand. The broader theme of deregulation under the current administration continues to create episodic but tradeable catalysts across healthcare services, biotech, and alternative medicine segments with surprising market velocity.